Politics & policy
Legislation & regulation
Pharm D Corner
John S. "Jack" Linehan of Epstein Becker Green on Copay Accumulators
Interview by Peter Wehrwein | July 21, 2019
4 Ways Hospitals Can Use Their Pharmacies To Cut Costs, Improve Care
Karen Kobelski | May 2, 2019
State legislatures spring ahead with restrictions on drug copay accumulators
John S. Linehan | April 16, 2019
PBMs Need To Be Disrupted, Not Disintermediated
Jake Frenz | March 28, 2019
What ICER Pricing Would Mean for U.S. Drug Spend
Nathan White, Mike Pace, Adam Johns, and Eric Latch | September 20, 2018
Health Advocates Can Learn Commitment to Social Justice From Merck CEO, Kenneth Frazier
Louis Tharp | August 18, 2017
Patient Centered and Paternalistic: Both/and is better than either/or.
Paul Terry | March 14, 2017
Unfairly Targeting 340B Hospitals
Ted Slafsky, MPP & Robert Chapman, MD | January 12, 2017
Rx: Pokémon Go?
Paul Terry | July 20, 2016
Changing the Standard of Care: Treating the Controlled Substance Crisis
Jonathan Gavras, MD | June 17, 2016
At a Crossroads? Which Reimbursement Pathway is Best Suited to Your Practice?
Aiden Spencer | June 9, 2016
Well-Being and the Next Industrial Revolution
Paul Terry | April 14, 2016
The Uberization of American Health Care: Why We Need a Disruptive Model
Anand Natampalli and Daniel A. Schulte | March 14, 2016
Health Insurers in the House at HIMSS ’16 Meet
Jan Greene | March 3, 2016
King v. Burwell Majority Opinion Shows Savvy About Insurance, Adverse Selection
Richard Mark Kirkner | June 25, 2015
The 340B Program Is Right on Track
Ted Slafsky | April 22, 2015
How Health Plans Can Keep Their Approach to New Markets Nimble, Collaborative, and Effective
Michael Flanagan | May 9, 2014
A Conversation with Uwe Reinhardt, PhD: Managed Care's Prospects in the Health Reform Era
Interview by Frank Diamond | September 18, 2013
Can Technology Really Save $240B?
Craig Keyes | September 1, 2013
Amgen Move Gives Biosimilars Big Boost
Neil Minkoff, MD | February 18, 2013
How ‘Special’ Are Specialty Drugs If They’re Most of Drug Spending?
Evidence Mounts for IL-23 and IL-17 Inhibitors As Treatment for Psoriasis
Cooking Up Some Value-based Care? Here Are Some of the Ingredients You Will Need.
High Hopes, Major Obstacles for PrEP and Ending HIV/AIDS as We’ve Known It
RA Patients Dissatisfied—But Maybe Resigned
View More >
Terms & Conditions of Use Agreement
Address and Subscription Changes
Managed Care News Archive
2019 Editorial Calendar
2019 Media Kit
2019 Space and Material Due Dates
Submitting Original Research
© 2019 MediMedia, an ICON plc company. All rights reserved.